# US 2024/0252476 A1 · Lpa1 antagonists for treating interstitial lung disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252476 A1
- Document ID: US20240252476A1
- Status: Published application
- Kind: A1
- Application number: 18/393,940
- Filed: 2023-12-22
- Published: 2024-08-01
- Earliest claimed: 2022-12-23
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Aryeh FISCHER; Steven GREENBERG; Ashfaq A. PARKAR; Daniel A. TATOSIAN; Giridhar S. TIRUCHERAI; Shiwei TAO
- Web page: https://patentgrep.com/patent/US20240252476A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/4192: 1,2,3-Triazoles
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This disclosure relates to methods of treating interstitial lung disease by administering an LPA1 antagonist to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the dosage to the standard daily dosage of the LPA1 antagonist.

## Claims

### Claim 1

A method of treating interstitial lung disease in a subject in need thereof, the method comprising administering an LPA1 antagonist to the subject at one or more daily dosages lower than the standard daily dosage during a dose titration period of treatment then increasing the daily dosage to the standard daily dosage of the LPA1 antagonist.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dose titration period of treatment is completed within 21 days.

### Claim at position 3

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the dose titration period of treatment comprises an initial period of treatment and a second period of treatment.

### Claim 8 (depends on 7)

The method of claim 7, wherein the initial period of treatment is completed within 7 days.

### Claim at position 6

-12. (canceled)

### Claim 13 (depends on 7)

The method of claim 7, wherein the second period of treatment is completed within 7 days.

### Claim at position 8

-17. (canceled)

### Claim 18 (depends on 7)

The method of claim 7, wherein the dose titration period of treatment further comprises a third period of treatment.

### Claim 19 (depends on 18)

The method of claim 18, wherein the third period of treatment is completed within 7 days.

### Claim 20 (depends on 18)

The method of claim 18, wherein the third period of treatment is completed within 4 days.

### Claim at position 12

-23. (canceled)

### Claim 24

A method of treating interstitial lung disease in a subject in need thereof, the method comprising administering an LPA1 antagonist to the subject at a daily dosage lower than the standard daily dosage during an initial period of treatment, followed by administering the dosage at a daily dosage higher than the initial period but lower than the standard daily dosage for a second period of treatment, then increasing the dosage to the standard daily dosage of the LPA1 antagonist.

### Claim 25 (depends on 24)

The method of claim 24, wherein the initial period of treatment and the second period of treatment are each independently completed within 7 days.

### Claim at position 15

-29. (canceled)

### Claim 30 (depends on 24)

The method of claim 24, wherein increasing the dosage comprises administering the dosage at a daily dosage lower than the standard daily dosage for a third period of treatment, then administering the standard daily dosage for a fourth period of treatment.

### Claim 31 (depends on 30)

The method of claim 30, wherein the third period of treatment is completed within 7 days.

### Claim at position 18

-35. (canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the LPA1 antagonist is administered once a day.

### Claim 37 (depends on 1)

The method of claim 1, wherein the LPA1 antagonist is administered twice a day.

### Claim 38 (depends on 1)

The method of claim 1, wherein the LPA1 antagonist is administered orally.

### Claim 39

(canceled)

### Claim 40 (depends on 1)

The method of claim 1, wherein the subject is being treated with one or more additional therapies for interstitial lung disease.

### Claim at position 24

-44. (canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the interstitial lung disease is idiopathic pulmonary fibrosis (IPF).

### Claim 46 (depends on 1)

The method of claim 1, wherein the interstitial lung disease is progressive pulmonary fibrosis (PPF).

### Claim 47 (depends on 1)

The method of claim 1, wherein the LPA1 antagonist is Compound A:
or a pharmaceutically acceptable salt thereof, and the standard daily dosage is about 120 mg/day of Compound A or an equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 48 (depends on 47)

The method of claim 47, wherein the standard daily dosage of Compound A is about 60 mg twice daily or an equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim 49 (depends on 7)

The method of claim 7, wherein the LPA1 antagonist is Compound A, or a pharmaceutically acceptable salt thereof, and wherein about 20 mg/day of Compound A, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered during the initial period of treatment.

### Claim 50 (depends on 7)

The method of claim 7, wherein the LPA1 antagonist is Compound A, or a pharmaceutically acceptable salt thereof, and wherein about 10 mg twice daily of Compound A, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered during the initial period of treatment.

### Claim 51 (depends on 7)

The method of claim 7, wherein the LPA1 antagonist is Compound A, or a pharmaceutically acceptable salt thereof, and wherein about 60 mg/day of Compound A, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered during the second treatment period.

### Claim 52 (depends on 7)

The method of claim 7 wherein the LPA1 antagonist is Compound A, or a pharmaceutically acceptable salt thereof, and wherein about 30 mg twice daily of Compound A, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered during the second treatment period.

### Claim 53 (depends on 47)

The method of claim 47, wherein Compound A comprises the crystal form characterized by at least one of the following:
a) single crystal structure having unit cell parameters substantially equal to
Crystal system,
Triclinic, P1
space group
Unit cell dimensions
a = 6.53 ± 0.10 {acute over (Å)}
alpha = 92.8 ± 1.0°
b = 13.06 ± 0.10 {acute over (Å)}
beta = 95.5 ± 1.0°
c = 14,04 ± 0.10 {acute over (Å)}
gamma = 93.0 ± 1.0°
Volume
1189(20) {acute over (Å)}3
Density (calculated)
1.239 g/cm3
Temperature
room temperature
wherein measurement of the single crystal structure is at room temperature;
b) a powder x-ray diffraction pattern substantially the same as shown in FIG. 1;
c) a powder x-ray diffraction pattern comprising 2 or more peaks at 2θ values selected from 6.4±0.2, 6.8±0.2, 9.6±0.2, 13.6±0.2, 15.7±0.2, 18.2±0.2, 19.9±0.2, 21.6±0.2, 24.8±0.2 and 26.8±0.2 (obtained at room temperature and CuKα λ=1.5418 Å);
d) a powder x-ray diffraction pattern comprising 3 or more peaks at 2θ values selected from 6.4±0.2, 6.8±0.2, 9.6±0.2, 13.6±0.2, 14.1±0.2, 14.5±0.2, 14.7±0.2, 15.7±0.2, 18.2±0.2, 18.7±0.2, 19.2±0.2, 19.9±0.2, 20.5±0.2, 21.6±0.2, 22.5±0.2, 23.1±0.2, 24.1±0.2, 24.8±0.2, 25.6±0.2, 26.8±0.2, 27.1±0.2 and 27.8±0.2 (obtained at room temperature and CuKα λ=1.5418 Å);
e) a differential scanning calorimetry thermogram substantially similar to the one as shown in FIG. 2;
f) a differential scanning calorimetry thermogram with an endotherm having an onset at about 152° C.; and/or
g) a thermal gravimetric analysis thermogram substantially similar to the one as shown in FIG. 3.

### Claim 54 (depends on 1)

The method of claim 1, wherein the subject experiences a smaller decline in forced vital capacity (FVC) after a treatment period compared to an untreated subject.

### Claim 55 (depends on 1)

The method of claim 1, wherein the subject experiences a greater time to first disease progression event after a treatment period than an untreated subject, wherein the first disease progression event is selected from:
absolute predicted forced vital capacity (ppFVC) decline of ≥10% from baseline;
acute exacerbation of lung fibrosis;
respiratory-related hospitalization; and
all-cause mortality.

### Claim at position 36

-57. (canceled)

### Claim 58

In a method of treating a subject with an LPA1 antagonist for treating interstitial lung disease, the improvement comprising: reducing the incidence of cardiovascular adverse events in the subject receiving the LPA1 antagonist by use of an initial dose escalation regimen comprising administering the LPA1 antagonist to the subject at a daily dosage lower than the standard daily dosage during an initial period of treatment then increasing the dosage to the standard daily dosage of the LPA1 antagonist.

### Claim 59 (depends on 58)

The method of claim 58, wherein the LPA1 antagonist is Compound A:
or a pharmaceutically acceptable salt thereof, and the standard daily dosage is about 120 mg/day of Compound A or an equivalent amount of a pharmaceutically acceptable salt thereof.

### Claim at position 39

-65. (canceled)
